|
NEW TESTS
Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. |
|||
|---|---|---|---|
| Test Code | Test Name | Effective Date | Page # |
| 14258 | AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma | 3/3/2025 | |
| 13694 | NPM1 Mutation for MRD, Quantitative PCR | 3/3/2025 | |
| 13817 | Plasma Renin Activity with Reflex to Aldosterone | 3/17/2025 | |
Note: It may be 24 - 48 hours after the published effective date before this test information is available on the Online Test Directory or in Quanum™.
AD-Detect™ ABeta 42/40 and p-tau217 Evaluation
Quest Diagnostics is pleased to introduce the most recent expansion of our Brain Health portfolio with the release of AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma. This profile contains both plasma beta-amyloid 42/40 ratio and p-tau217. In a Quest-run validation study, these biomarkers combined show an enhanced accuracy of over 90% sensitivity and specificity to meet the CEOi recommendations. Independent measurement and interpretation of plasma amyloid ratios (AB42/40) and phosphorylated tau levels (p-tau181 and p-tau217) provide clinically valuable insight into patient risk for development of Alzheimer’s disease. Combining these core AD pathological markers for a single analytical interpretation has been shown to significantly improve predictive performance and accuracy for detecting amyloid positivity and confirming a diagnosis of Alzheimer’s disease. Improving patient outcomes and care pathways drives Quest Diagnostics’ continued expansion of accessible AD and dementia assessments within our blood-based offerings. Visit QuestForTheCure.com to see how we are continuing to transform cognitive health assessment and diagnostics.
NPM1 Mutation, Quantitative, PCR
Quest Diagnostics is pleased to announce the launch of NPM1 Mutation, Quantitative PCR, an allele specific qPio.CR assay that is used in post-remission MRD monitoring of patients diagnosed with Acute Myeloid Leukemia (AML). MRD monitoring is essential in guiding post-remission therapy and identifying potential early relapse in AML patient management, therefore this is a critical and timely addition to the Quest Oncology Portfolio.
Plasma Renin Activity
Quest Diagnostics is pleased to announce the launch of the Plasma Renin Activity (PRA) Reflex to Aldosterone, LC-MS/MS test. Primary Aldosteronism (PA) is underrecognized and the most common cause of secondary hypertension. Patients with untreated PA are at a disproportionately higher risk of cardiovascular, kidney and metabolic disease when compared to essential hypertensive patients.
The following tests will be available through Quest Diagnostics on the dates indicated below.
| AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Significance | Intended use is for Alzheimer's Diagnosis. Independent measurement and interpretation of plasma amyloid ratios (AB42/40) and phosphorylated tau levels (p-tau181 and p-tau217) provide clinically valuable insight into patient risk for development of Alzheimer’s disease. However, by combining core AD pathological markers for a single analytical interpretation have been shown to significantly improve predictive performance and accuracy for detecting amyloid positivity and confirming a diagnosis of Alzheimer’s disease. The AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma evaluates a patient’s plasma AB42/40 ratios and p-tau217 levels reporting out the likelihood that a symptomatic patient suspected of AD has a High, Indeterminant, or Low likelihood of amyloid pathology consistent with AD. This panel meets established performance criteria for confirming a diagnosis of Alzheimer’s disease utilizing plasma biomarkers. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Effective Date | 3/3/2025 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Test Code | 14258 | ||||||||||||||||||||||||||||||||||||||||||||||||
| CPT Codes | 82233, 82234, 84393 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Requirements | 2 mL (1.1 mL minimum) plasma collected in a K2 EDTA (lavender-top) tube | ||||||||||||||||||||||||||||||||||||||||||||||||
| Reject Criteria | Moderate or gross hemolysis; specimen collected in a glass, polystyrene, or polycarbonate tube | ||||||||||||||||||||||||||||||||||||||||||||||||
| Instructions |
Patient Preparation: Patients should be cautioned to stop biotin consumption at least 72 hours prior to collection of a sample Instructions: Quest Diagnostics does not perform this test for individuals under the age of 18. Pre-test and post-test counseling is strongly recommended. Collect blood into a K2 EDTA plasma tube and mix by inversion 10 times. Centrifuge to separate plasma from cells within 1 hour of collection. Carefully transfer plasma into 2 separate polypropylene tubes or 2 separate Quest issued polypropylene pour-off/transfer tubes. Do not transfer to conical tubes. If unable to centrifuge within 1 hour of collection, store tube on ice. Store frozen. |
||||||||||||||||||||||||||||||||||||||||||||||||
| Transport Temperature | Frozen | ||||||||||||||||||||||||||||||||||||||||||||||||
| Specimen Stability |
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Set-up/Analytic Time | Set up: Mon-Sat; Report available: 3-5 days | ||||||||||||||||||||||||||||||||||||||||||||||||
| Reference Range |
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Methodology | Liquid Chromatography/Tandem Mass Spectrometry, Immunoassay | ||||||||||||||||||||||||||||||||||||||||||||||||
| Performing Site | Quest Diagnostics Nichols Institute, San Juan Capistrano | ||||||||||||||||||||||||||||||||||||||||||||||||
| Interface Mapping |
|
||||||||||||||||||||||||||||||||||||||||||||||||
| NPM1 Mutation for MRD, Quantitative PCR | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Significance | NPM1, encoding the nucleophosmin protein, is mutated in about 30% of the AML patients and the mutations are predominantly a 4-base insertion which causes a frameshift of the NPM1 protein at amino acid sequence 288 near the C-terminus. NPM1, Quantitative for MRD is an allele-specific qPCR assay designed to quantitatively detect the presence of the NPM1 mutation found previously as a way to assess the minimal/measurable residual disease (MRD) status after initial induction therapy for prognosis of disease progression and consideration of consolidation treatment selection. | ||||||||||||||||||||||||||||||||||||
| Effective Date | 3/3/2025 | ||||||||||||||||||||||||||||||||||||
| Test Code | 13694 | ||||||||||||||||||||||||||||||||||||
| CPT Codes | 81310 | ||||||||||||||||||||||||||||||||||||
| Specimen Requirements |
Preferred: 5 mL (3 mL minimum) whole blood or 3 mL (1mL minimum) bone marrow collected in an EDTA (lavender-top) tube Acceptable: Whole blood or bone marrow collected in a sodium heparin (green-top) tube or 50 uL (20 uL minimum) of 10 ng/uL extracted RNA submitted in a microcentrifuge tube |
||||||||||||||||||||||||||||||||||||
| Instructions |
Do not reject. Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Extracted RNA: In addition, only accept extracted DNA when extraction or isolation is performed in an appropriately qualified laboratory such as a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or CMS. |
||||||||||||||||||||||||||||||||||||
| Transport Temperature |
Blood and Bone marrow: Room temperature RNA: Frozen |
||||||||||||||||||||||||||||||||||||
| Specimen Stability |
|
||||||||||||||||||||||||||||||||||||
| Set-up/Analytic Time | Set up: Daily; Report available: 5-7 days | ||||||||||||||||||||||||||||||||||||
| Reference Range |
|
||||||||||||||||||||||||||||||||||||
| Methodology | Polymerase Chain Reaction | ||||||||||||||||||||||||||||||||||||
| Performing Site | Quest Diagnostics Nichols Institute, San Juan Capistrano | ||||||||||||||||||||||||||||||||||||
| Interface Mapping |
|
||||||||||||||||||||||||||||||||||||
| Plasma Renin Activity with Reflex to Aldosterone | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Significance | The Aldosterone-renin ratio is used to screen for primary aldosteronism. | ||||||||||||||||||||||||||||||
| Effective Date | 3/17/2025 | ||||||||||||||||||||||||||||||
| Test Code | 13817 | ||||||||||||||||||||||||||||||
| CPT Codes | 84244 | ||||||||||||||||||||||||||||||
| Specimen Requirements | 1.8 mL (0.8 mL minimum) frozen plasma collected in an EDTA (lavender-top) tube | ||||||||||||||||||||||||||||||
| Reject Criteria | Moderate to gross hemolysis; plasma collected in a plasma separator tube; received thawed | ||||||||||||||||||||||||||||||
| Instructions | Collect a mid-morning blood sample after patient has been upright (sitting, standing, or walking) for a minimum of 2 hours, then have them sit 5-15 minutes prior to collection | ||||||||||||||||||||||||||||||
| Transport Temperature | Frozen | ||||||||||||||||||||||||||||||
| Specimen Stability |
|
||||||||||||||||||||||||||||||
| Set-up/Analytic Time | Set up: Sun-Fri; Report available: 4-6 days | ||||||||||||||||||||||||||||||
| Reference Range |
See Laboratory Report |
||||||||||||||||||||||||||||||
| Methodology |
Chromatography/Mass Spectrometry Reflex: Liquid Chromatography/Tandem Mass Spectrometry |
||||||||||||||||||||||||||||||
| Performing Site | Quest Diagnostics Nichols Institute, Chantilly | ||||||||||||||||||||||||||||||
| Interface Mapping |
|
||||||||||||||||||||||||||||||
| Additional Information | If Plasma Renin Activity result is <1.00 ng/mL/h, then Aldosterone will be performed at an additional charge (CPT code(s): 82088). | ||||||||||||||||||||||||||||||